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Precise dose delivery of col ist imethate sodium using a prototype 
I -neb TM AAD ~ system 
R. Potter, R.H.M. Hatley 
P@le Therapeutics. a Respironics company. Bognor Regis. West Sussex. UK 
Inr mduetlon The I-neb TM AAD ® (Adaptive Aerosol Delivery, Profile Therapeutics) 
system is designed to deliver a precise, reproducible dose into the inspkatory 
portion of a patient's breathing pattem, with the delivered dose t by the size of the 
medication chamber. Gr avimetric (Gray) screening is a useful tool for assessing the 
output of drugs that do not denature. We tested the ability of 3 prototype I neb 
devices to deliver a 0.3 MIU dose of colistimethate sodium using both bioassay and 
gr avimetric meas~arement s. 
Method Tbree prototype I neb devices were each fitted with a 300 ~tL medication 
chamber and filled with 1 MIU colistimethate sodium (Promixin TM, Profile 
Pharma), reconstituted with 1 mL of deionized water. Each device was weighed 
prior to being tested using a Harvard pump set to generate the CEN breathing 
pattern. Emitted aerosol was collected upon a filter, which was eluted for analysis 
using a bioassay. Each device was re weighed at the end of each test to allow 
calculation of the Gray dose. Aerosol particle size was meas~ared separately using a 
laser particle sizer. 
Results Average measured activity was 0.325 MIU (95% CI 0.313 MIU to 
0.337 MIU), and average Gray dose (corrected for density) was 0.316 g (95% CI 
0.302 g to 0.330 g). All the doses were within +20% of the nominal dose, the Gray 
dose approximated the bioassay dose. The MMI) of the emitted aerosol was 
3.28 ~tm and 80.7% of particle mass was below 5 ~tm. 
Conclusion The I neb AAD system is able to deliver precise, reproducible doses of 
colistimethate sodium ha an aerosol that has p rticle size characteristics suitable for 
delivery into the lung. Gr avimetric output can be used as a rapid screening tool to
determine aerosol output, as long as post nebulisation protein integrity has been 
established. 
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Assessment  of nebulisaSon eff iciency of a reduced Glutathion- 
Sodium solution (GSH) by a PARI LC STAR ~ and the eFIow~electronic 
nebuliser 
M. Keller, A. B alcke, A. Bucholsld, M. I4mc~h 
PARI GmbH. Aerosol Research Institute. Steinerstr I5c. 81369 Munich. Germany 
Aims: Reduced GSH is claimed to have anti inflammatory mad anti oxidative 
effects when delivered ha respirable doses > 100 mg to the lungs of CF patients. 
This study was undertaken to obtain information on aerosol characteristics 
regarding: Respkable Fraction (RF % of droplets below 5 ~tm), Mass Median 
Diameter (MMI)), Delivered Dose (DD), Respirable Dose (RD drug in droplets 
< 5 ~tm) mad Respkable Drug Delivery Rate (RDDR). Methods: Physical properties 
of a 646 mg GSH Na solution ( 600 mg GSH) in 3 ml water were as follows: pH 
7, osmolality 1.245 osmol/kg, dyn. viscosity 2.1 mPas, surface tension 73.8 raN/m, 
density 1.37 g/ml. An adult and a child breathing pattern (15 and 25 breaths/rain at
500 and 2CO ml, inh. :exh. 1:1 ) were applied uring nebulisation of 3 ml GSH Na 
by a PARI LC STAR e / PARI BOY ® N compressor and an adapted eFlow ® (L35) 
electronic nebuliser (PARI Stanaberg, Germany). Droplet size distribution was 
assessed by laser diflYaction and the drug quantified by a HPLC method utilising 
ELSD detection. Results: Adult breathing pattem results for the LC STAR e vs. 
eFlow ® were as follows: RF 80.9 vs. 83.6%, MMI) 2.9 vs. 3.3 ~tm, GSD 2.4 vs. 1.5, 
DD 167.5 vs. 361.9 rag; RD 135.6 vs. 302.7 rag, RDDR 13.2 vs. 40.3 mgJmin, 
nebulisation time 10.4 vs. 7.5 min. Results for the child breathing pattern were 
essentially the same for eFlow ®, but about 18% lower for the LC STAR e regarding 
DD, RD and RDDR. Conduslons: Drug delivery by eFlow ® does not depend on the 
breathing pattern and is more than 2 fold more fficient compared to the LC STAR e 
regarding the delivery of drug in respkable droplets per unit time. The therapeutic 
benefit of GSH administered by eFlow ~ is planned to be clinically tested. 
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In-vitro deposiSon study of a novel antibiotic solution into nasal cast 
cavities by the PARI S INUS TM 
U. Schuschnig, M. Luber, Y. Waehner, H. Mentzel, A. Raposo, M. Keller 
PARI AerosoI Research Institute. Steinerstr I5c. 81369 Munich. Germany 
Aims:  1: predict drug deposition ha the nasal cavities depending on their orifice 
diameter, volume and location and 2: to create a reproducible and robust 
char acterisation method for rug formulations nebulised by the PARI SINUS TM 
Methods: A cast model based on anatomical dimensions was developed, ha order to 
reduce experimental work, the model contained four cavities (sinuses) in every 
position (t¥ont al, maxillary and sphenoid). The cavities as well as the orifices (ostia) 
were exchangeable, allowing variation of the sinus volume and ostium diameter. 
The effect of volume (5, 14 and 25 ml), orifice diameter (0.5, 1.0 and 2.0 ram) and 
location (frontal, maxillary and sphenoid) on deposition was studied ha an 
experimental design. Alter 10 minutes nebulisation by the SINUS TM P (PAP.I, 
Starnberg, Germany), filled with 3 ml of an aqueous antibiotic drug solution, the 
cavities were disassembled from the model, and drug inside was extracted with 
solvent and assayed by HPLC. Drug deposited on the ostium was not accounted. 
Aerosol characteristics were assessed by laser diffraction. Both, experimental 
design and data analysis were performed using Statgr aphics Plus. 
Results: Drug deposition inside the single cavities ranged between 20 450 ~tg with 
a mean of 120 pg. Multiple regression analysis of the data revealed significant 
dependence ofdeposition on volume (p~).C(~)) and aperture (p 0.0(201). Effect of 
location was insignificant (p 0.32). Average drug deposition in 12 cavities of the 
model was 1450 + 150pg (n~) .  Mean droplet size of the aerosol was 3.1 ~tm with 
76% below 5 ~tm mad 32 % below 2 ~tm. 
Conclusions: Results indicate that drugs can be delivered to the sinuses, even to 
those with small ostium diameter and volume. 
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In-Vitro equivalence and shorter nebulization t ime using a novel 
tobramycin formulation (150 mg/1 .5  ml) in an eFIow ~ electronic 
nebulizer compared to TOBI ~ nebulized by the PARI LC PLUS ~ 
A. BucholskJ, M. Keller, G. Lang, H. Meyer, U. Schusclmig 
PARI AerosoI Research Institute, Munich, Germany 
Aims: TOBI ~ (300 nag tobramycin in 5 ml) in combination with the PAILI LC PLUS ~ is the 
only FDA approved ilflaaled antibiotic therapy for the trealanent of chronic pzeudomolaas 
aemginosa infections in CF patients. The cunent in vitro study was maderiaken to assess 
performance of the eFlow ~ electa~)nic nebulizer in combination with a novel aqueous 
preservative free tobramycin formulation. 
Met hc~: Delivered (DD) mad Rezpirable Do~s (R1)) were measured dtwing zimulat~ed breaflaing 
(tidal volume 500 ml, 15 breathztmin, zfl~al./exhal, r tio 1:1). The c~plet size distribution wag 
assessed by laser diffr~ficta (Malvem MasterSizerX) at a constant flow f ?0 l/rain. 
Results: A Respirable Doze of 83.2 vs. 71.2 nag tobramycin is obtained with the novel 
dnlg/device combination compared to TOBI ® with LC PLUS ®, whereas the amounts of dnlg 
found in comze (> 5~tm) and very fine droplets (< 2~rn) are both less for eFlow ~ vs. LC 
PLUS ~ (')3.5 vs. 43.1 nag i  comze mad, 6.4 vs. ?0.1 nag in fine droplets, respectively). 
Respirable Drag Delivery Rate (RDDR) is 6 fold higher with eFlow ~ allowing for a much 
faster admilfi slrafion of the novel formulation  the lungs (').7 rain vs. 13.3 rain). 
Tobt amycin 150 rag/15 ml TOBI e 300 mg/5 0 ml 
customized Flow ~ (n 6) pAR/LC pLtIS ~ (n 12) 
Nebulizer typ ° mean SD mean SD 
DD [rag] 1067 733 1142 622 
RD [rag <5 bm] 83 2 416 712 626 
RDDR [rag < 5 bm/min] 308 113 54 026 
Aer ¢~ol l¢~ses [mg] 28 2 507 577 5 58 
Nebulization time [min] 27 030 133 091 
MMD [bm] 364 008 400 021 
GSD 149 001 200 009 
RF [% < 5 bm] 78 0 163 623 237 
Conclusions: The results indicate that a tobrarnycin do~e of 150 my in 1.5 ml with a 
customized eFlow ~ yields a aimilm in vitro respirable do~e compared to the approved 
Ucealinent regime (300 ms/5 ml in a jet nebulizer). A lfigher amount delivered n droplets 
between 2 Bm and 5 Bm suggests improved drug targeting and the potential for reduced aide 
effects. The aborter Ucealinent time helps to reduce the burden on CF patients ta!dng their 
iz~lmled medications and may increase therapy compliance and quality of life. 
